Cargando…

Prevalence of potential drug–drug interactions in cancer patients treated with oral anticancer drugs

BACKGROUND: Potential drug–drug interactions (PDDIs) in patients with cancer are common, but have not previously been quantified for oral anticancer treatment. We assessed the prevalence and seriousness of potential PDDIs among ambulatory cancer patients on oral anticancer treatment. METHODS: A sear...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Leeuwen, R W F, Brundel, D H S, Neef, C, van Gelder, T, Mathijssen, R H J, Burger, D M, Jansman, F G A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3619066/ https://www.ncbi.nlm.nih.gov/pubmed/23412102 http://dx.doi.org/10.1038/bjc.2013.48

Ejemplares similares

Inhibition of endosomal sequestration of basic anticancer drugs: influence on cytotoxicity and tissue penetration
por: Lee, C M, et al.
Publicado: (2006)

Pharmacologically directed strategies in academic anticancer drug discovery based on the European NCI compounds initiative
por: Hendriks, Hans R, et al.
Publicado: (2017)

Camptothecin suppresses NRF2–ARE activity and sensitises hepatocellular carcinoma cells to anticancer drugs
por: Chen, Feng, et al.
Publicado: (2017)

Se-methylselenocysteine offers selective protection against toxicity and potentiates the antitumour activity of anticancer drugs in preclinical animal models
por: Cao, S, et al.
Publicado: (2014)

Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels
por: Giovannetti, E, et al.
Publicado: (2007)

A model of quiescent tumour microregions for evaluating multicellular resistance to chemotherapeutic drugs
por: Mellor, H R, et al.
Publicado: (2005)

Comparative drug screening in NUT midline carcinoma
por: Beesley, A H, et al.
Publicado: (2014)

Sigma-2 receptor ligand as a novel method for delivering a SMAC mimetic drug for treating ovarian cancer
por: Zeng, C, et al.
Publicado: (2013)

Enzastaurin inhibits tumours sensitive and resistant to anti-EGFR drugs
por: Gelardi, T, et al.
Publicado: (2008)

Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma
por: Tavanti, E, et al.
Publicado: (2013)

Surface proteomic analysis of osteosarcoma identifies EPHA2 as receptor for targeted drug delivery
por: PosthumaDeBoer, J, et al.
Publicado: (2013)

Drug-induced senescence bystander proliferation in prostate cancer cells in vitro and in vivo
por: Ewald, J A, et al.
Publicado: (2008)

In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs
por: Ashley, D M, et al.
Publicado: (2008)

CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers
por: Smith, L M, et al.
Publicado: (2008)

Development of a cyclin-dependent kinase inhibitor devoid of ABC transporter-dependent drug resistance
por: Kaliszczak, M, et al.
Publicado: (2013)

Histamine, a vasoactive agent with vascular disrupting potential, improves tumour response by enhancing local drug delivery
por: Brunstein, F, et al.
Publicado: (2006)

Clinically relevant drug interactions with multikinase inhibitors: a review
por: Hussaarts, Koen G. A. M., et al.
Publicado: (2019)

Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts
por: Vlahovic, G, et al.
Publicado: (2007)

Rapid in vivo testing of drug response in multiple myeloma made possible by xenograft to turkey embryos
por: Farnoushi, Y, et al.
Publicado: (2011)

Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin
por: Colmegna, B, et al.
Publicado: (2015)

Downregulation of drug transport and metabolism in mice bearing extra-hepatic malignancies
por: Sharma, R, et al.
Publicado: (2008)

Choline kinase-alpha by regulating cell aggressiveness and drug sensitivity is a potential druggable target for ovarian cancer
por: Granata, A, et al.
Publicado: (2014)

Contribution of HIF-1 and drug penetrance to oxaliplatin resistance in hypoxic colorectal cancer cells
por: Roberts, D L, et al.
Publicado: (2009)

Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer
por: Simpson, G R, et al.
Publicado: (2012)

Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs
por: Bianco, R, et al.
Publicado: (2008)

Drug-induced caspase 8 upregulation sensitises cisplatin-resistant ovarian carcinoma cells to rhTRAIL-induced apoptosis
por: Duiker, E W, et al.
Publicado: (2011)

The involvement of FOXO1 in cytotoxic stress and drug-resistance induced by paclitaxel in ovarian cancers
por: Goto, T, et al.
Publicado: (2008)

Glutathione S-transferase P1 (GSTP1) directly influences platinum drug chemosensitivity in ovarian tumour cell lines
por: Sawers, L, et al.
Publicado: (2014)

p53-dependent and p53-independent anticancer effects of different histone deacetylase inhibitors
por: Sonnemann, J, et al.
Publicado: (2014)

Assessing proliferation, cell-cycle arrest and apoptotic end points in human buccal punch biopsies for use as pharmacodynamic biomarkers in drug development
por: Camidge, D R, et al.
Publicado: (2005)

Towards better dose individualisation: metabolic phenotyping to predict cabazitaxel pharmacokinetics in men with prostate cancer
por: Janssen, A, et al.
Publicado: (2017)

CYP1B1 expression is induced by docetaxel: effect on cell viability and drug resistance
por: Martinez, V G, et al.
Publicado: (2008)

Molecular targets for anticancer redox chemotherapy and cisplatin-induced ototoxicity: the role of curcumin on pSTAT3 and Nrf-2 signalling
por: Fetoni, A R, et al.
Publicado: (2015)

PET imaging of patients with non-small cell lung cancer employing an EGF receptor targeting drug as tracer
por: Memon, A A, et al.
Publicado: (2011)

Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents
por: Chatelut, E, et al.
Publicado: (2012)

Combined effects of GSTP1 and MRP1 in melanoma drug resistance
por: Depeille, P, et al.
Publicado: (2005)

Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo
por: Steele, N, et al.
Publicado: (2009)

Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs
por: Iwasa, T, et al.
Publicado: (2010)

The retinoid anticancer signal: mechanisms of target gene regulation
por: Liu, T, et al.
Publicado: (2005)

Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes
por: Calcagno, A M, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_pi75bt91v6ba85ko42ddocah71